Naringenin (Nar) down-regulated EMT markers expression in both mRNA and protein levels by inhibiting TGF-β1/Smad3 signal pathway in the pancreatic cancer cells. This evidence concerns the gene SMAD3 and familial pancreatic carcinoma.